Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
Myrbetriq Plus Pelvic Floor Exercises Fail to Ease Overactive Bladder
Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were able to expel with each urination, relative to patients using only pelvic floor exercise. But this benefit was temporary. Read more.
Source: Parkinson’s News Today, December 7, 2022
Symptomatic Covid-19 Infection Is Associated With An Increased Risk Of Overactive Bladder Symptoms
A new study finds that symptomatic Covid-19 infection is associated with the risk of developing or exacerbating overactive bladder symptoms. As an overlooked area of study, only a handful of investigations have focused on the impact of Covid-19 infection on the urinary system. Previous studies have found increased urinary tract symptoms, including the frequency, urgency, and waking up to urinate, post Covid-19 infection; they attributed the symptoms to inflammation and described the condition as Covid-Associated Cystitis (CAC). Read more.
Source: Forbes, December 5, 2022
Overactive Bladder Linked to Multiple Unmet Socioeconomic Needs
Unmet socioeconomic needs had a significant association with overactive bladder (OAB), adding to evidence of a complex interaction between social determinants of health and OAB, researchers said. Stressors such as housing and food insecurity and concerns about personal health as much as tripled the odds of reported OAB symptoms. The stressors remained significant predictors for OAB after adjustment for multiple demographic and medical factors. Unmet socioeconomic needs had a stronger association with OAB with urge urinary incontinence (UUI, “wet” OAB), reported Elisabeth M. Sebesta, MD, of Vanderbilt University Medical Center in Nashville, Tennessee, and co-authors in the Journal of Urology. Read more.
Source: MedPage Today, December 1, 2022
UroMems Initiates First-in-Human Study of Its Smart Implant to Treat Stress Urinary Incontinence
UroMems, a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) investigational device to treat SUI. This initial clinical study is a key milestone in the development of UroActive. Read more.
Source: PRNewswire, November 29, 2022
FDA Classifies Baxter’s Hospital Bed System Recall As Most Serious
The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc (BAX.N), as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient’s caregiver of involuntary urination or defecation, by sending a correction letter to its customers in late September. Read more.
Source: Reuters, November 23, 2022
Coloplast to Introduce SpeediCath Flex Set Catheter in US
Danish medical device company Coloplast is set to launch its new SpeediCath Flex Set catheter in the US this month. The new catheter is a gentle, all-in-one solution that has been developed for people living with bladder and urinary problems. It features a no-touch dry sleeve as well as an omnidirectional tip, which can bend to follow the curves of the urethra. The SpeediCath Flex Set has a soft-squeeze grip that safely guides the tip into the urethra without making contact. It helps patients catheterise at home or away and also supports them in managing conditions and sustaining healthy lifestyles. Read more.
Source: Medical Device Network, November 21, 2022
TENA Launches Lights Sensitive Ultra Pads Tackling a Lesser-Known Menopause Symptom
TENA, the UKs leading incontinence brand for over 60 years, has launched a new range of Lights Sensitive Ultra Pads, designed to manage bladder leaks and support healthy intimate skin. This latest product innovation features a unique skin caring emulsion that has been specifically designed for sensitive skin by helping to limit friction, making it the first of its kind to the UK market. Continuing in its mission to better support women during the menopause, the introduction of the TENA Lights Sensitive Ultra will help the large number of women who suffer with skin irritation and incontinence – two of the many lesser-known menopausal symptoms. Read more.
Source: Retail Times, November 19, 2022